Futura Medical plc announces that the Mexican Secretariat of Healthhas granted over the counter sale ("OTC") Marketing Authorisation for Eroxon®, the Company's break through, topical gel formulation for the treatment of erectile dysfunction ("ED"). Eroxon® can now be marketed in Mexico as a topical treatment for ED available OTC without the need for a prescription. Eroxon® is approved as an effective, clinically proven treatment for ED with a 10-minute onset of action.

The prevalence of ED disrupts the lives of at least 1 in 5 men globally. Mexico currently has a population of 129 million. MED3000 has already been approved as the first pan-European clinically proven topical treatment for ED available OTC and is now available in a growing number of EU and Middle East markets.

Initial launches commenced under the brand name Eroxon®in March 2023, with commercial agreements in key markets including the European Economic Area, UK, Switzerland, South Korea, Latin America and the Middle East.